Skip to main content
ASSTON PHARMACEUTICALS LIMITED logo

ASSTON PHARMACEUTICALS LIMITED — Investor Relations & Filings

Listed
Ticker · 544445 ISIN · INE0SJX01015 BSE.NS Manufacturing
Open in API
Filings indexed 6 across all filing types
Latest filing 2026-06-24 Capital/Financing Update
Country IN India
Listing BSE.NS 544445 · 2 venues

About ASSTON PHARMACEUTICALS LIMITED

https://asstonpharmaceuticals.com

Asston Pharmaceuticals Limited is a pharmaceutical entity engaged in the development, manufacturing, and distribution of a diverse range of healthcare products. The company focuses on multiple therapeutic segments, including anti-infectives, analgesics, anti-inflammatory medications, and nutritional supplements. Its product portfolio comprises various dosage forms such as tablets, capsules, liquid orals, and injectables, produced in compliance with rigorous quality control standards. The organization is dedicated to providing accessible and effective medicinal formulations to address a variety of clinical requirements. By leveraging its manufacturing infrastructure, the company supplies generic medications and specialized healthcare solutions to a broad client base. Asston Pharmaceuticals maintains a focus on operational excellence and product safety to ensure the delivery of reliable therapeutic options to the healthcare sector.

Recent filings

Filing Released Lang Actions
Trading Window Closure
Capital/Financing Update Classification · 95% confidence The document is a formal communication addressed to the stock exchange listing/compliance department informing about a scheduled Board Meeting. The agenda includes a proposal for raising funds through methods such as preferential issue, contingent on regulatory and shareholder approvals. Additionally, it notifies the closure of the trading window in compliance with insider trading regulations. It does not present any financial data or detailed reports. The document is essentially an announcement related to upcoming capital raising plans and trading restrictions, which aligns with an update on capital/financing activities. Therefore, it should be classified as a Capital/Financing Update (CAP). The length is short and the content is clearly an announcement, not an actual capital raising report or financial statement.
2026-06-24 English
Asston Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/07/2026 ,inter alia, to consider and approve proposal for raising ....
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to the stock exchange (BSE Limited) notifying about an upcoming Board Meeting to discuss raising funds and the closure of the trading window due to insider trading regulations. The content references Regulation 29 of SEBI's Listing Obligations which governs disclosure of Board meeting dates and trading windows. There is no actual report or financials presented; instead, it is an announcement of an imminent board meeting and related procedural disclosures. The document fits best into the category of 'Capital/Financing Update' since the Board meeting will consider raising funds via preferential issue. Hence, the classification is CAP.
2026-06-24 English
Audited Financial Results for the Financial Year ended 31st March, 2026
Interim / Quarterly Report Classification · 92% confidence The document is a SEBI Listing compliance letter dated May 29, 2026, disclosing the outcome of the Board Meeting and attaching the Audited Financial Statements and Financial Results (including half‐year and full‐year figures) together with the Independent Auditor’s Report, pursuant to Regulation 33 of the SEBI Listing Regulations. It contains substantive financial data and statements rather than merely announcing publication or providing a link. This is a periodic (half‐year/quarterly and year‐to‐date) financial report submission, which corresponds to an Interim/Quarterly Report. FY 2026
2026-05-29 English
Audited Financial Results for the Financial Year ended 31st March, 2026
Interim / Quarterly Report Classification · 94% confidence The document is a stock‐exchange filing under SEBI LODR Regulation 30/33 announcing and enclosing the audited financial statements and audit report for the half-year ended 31 March 2026 (along with year-to-date results). It contains full financial data (statement of financial results) plus the auditor’s report (independent auditor’s opinion). Under our taxonomy, an IR classification covers comprehensive interim/quarterly (or half-yearly) financial reports with actual financial statements, distinguishing it from a mere publication announcement or full annual report. FY 2026
2026-05-29 English
Outcome of Board Meeting scheduled to be held on 29th May, 2026
Interim / Quarterly Report Classification · 85% confidence The document is a SEBI Listing Regulation disclosure under Regulation 30/33 announcing board approval of audited financial statements and financial results for the half year and year ended 31 March 2026, and it includes the auditor’s report and full statement of financial results. It is not a full annual report (10-K) or a simple earnings teaser, nor merely an announcement of publication. It contains substantive financial data for an interim period (half year) and year-to-date results, fitting the definition of an Interim/Quarterly Report. FY 2026
2026-05-29 English
Asston Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve 1. To consider and approve ....
Regulatory Filings Classification · 85% confidence The document is an official intimation under SEBI Listing Obligations (Regulation 29) notifying the stock exchange of a forthcoming Board of Directors meeting to consider and approve financial statements. It does not itself contain financial results, executive compensation, or a report, nor does it announce board member changes. It is a compliance/regulatory announcement and thus falls under the general Regulatory Filings category.
2026-05-21 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.